Mathur V

No ORCID on file · 4 papers in corpus
rct 2024
Two-year efficacy and safety of relugolix combination therapy in women with endometriosis-associated pain: SPIRIT open-label extension study
Human Reproduction ·doi:10.1093/humrep/dead263

STUDY QUESTION: What is the efficacy and safety of long-term treatment (up to 2 years) with relugolix combination therapy (CT) in women with moderate to severe endometriosis-associated pain? SUMMARY ANSWER: For up to 2 years, treatment wit…

article 2023
A Plain Language Summary to learn about relugolix combination therapy for the treatment of pain associated with endometriosis
Pain management ·doi:10.2217/pmt-2023-0052

WHAT IS THIS SUMMARY ABOUT?: This is a summary of research studies (known as clinical trials) called SPIRIT 1 and SPIRIT 2. The SPIRIT 1 and SPIRIT 2 studies compared how well a medicine called relugolix combination therapy worked in reliev…

rct 2022
Once daily oral relugolix combination therapy versus placebo in patients with endometriosis-associated pain: two replicate phase 3, randomised, double-blind, studies (SPIRIT 1 and 2)
Lancet (London, England) ·doi:10.1016/s0140-6736(22)00622-5

BACKGROUND: Endometriosis is a common cause of pelvic pain in women, for which current treatment options are suboptimal. Relugolix, an oral gonadotropin-releasing hormone receptor antagonist, combined with estradiol and a progestin, was eva…

2008
Pelvic congestion syndrome: diagnosis and treatment.
Seminars in interventional radiology ·doi:10.1055/s-0028-1102998

The diagnosis of pelvic congestion syndrome (PCS) continues to challenge all physicians involved especially those in such specialties as anesthesia, gastroenterology, general surgery, obstetrics and gynecology, and interventional radiology.…